NCT03875287View on ClinicalTrials.gov

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

January 2, 2026

Study Completion Date

December 1, 2026

Conditions
Solid Tumor
Interventions
DRUG

Decitabine

"DOSING REGIMEN(S):~Level -1 10mg daily days 1-4~Level 1 10mg daily days 1-5~Level 2 15mg daily days 1-5~Level 3 20mg daily days 1-5~Level 4 25 mg daily days 1-5"

DRUG

Cedazuridine

"DOSING REGIMEN(S):~Level -1 100mg daily days 1-4~Level 1 100mg daily days 1-5~Level 2 100mg daily days 1-5~Level 3 100mg daily days 1-5~Level 4 100mg daily days 1-5"

Trial Locations (2)

21231

RECRUITING

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

90089

RECRUITING

USC Norris Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER